Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Variation in the Aquaretic Efficacy of Tolvaptan in Healthy Adults

Trial Profile

Variation in the Aquaretic Efficacy of Tolvaptan in Healthy Adults

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Oct 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tolvaptan (Primary) ; Sodium chloride
  • Indications Autosomal dominant polycystic kidney disease; Cardiac oedema; Hyponatraemia; Renal failure
  • Focus Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 26 Sep 2016 Status changed from recruiting to completed.
    • 26 Feb 2015 Planned primary completion date changed from 1 Sep 2014 to 1 Sep 2015 as reported by ClinicalTrials.gov record.
    • 12 Nov 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top